Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor (GISTs)
Phase II Multicenter Clinical Trial on Imatinib Treatment for Patients With Resectable Hepatic Metastasis From Gastrointestinal Stromal Tumors (GISTs)
Sponsor: Niigata University Medical & Dental Hospital
This PHASE2 trial investigates Gastrointestinal Stromal Tumor and Metastatic Cancer and is currently completed. Niigata University Medical & Dental Hospital leads this study, which shows 8 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Aug 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Aug 2023 [monthly]
Completed PHASE2
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
-
May 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — May 2018 [monthly]
Completed PHASE2
First recorded
Oct 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Niigata University Medical & Dental Hospital
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Chūō, Japan , Fukuoka, Japan , Fukushima, Japan , Hamamatsu, Japan , Hidaka, Japan , Hirosaki, Japan , Jōetsu, Japan , Kagoshima, Japan , Kanigyou-ku, Japan , Kisarazu, Japan and 21 more locations